Foghorn Therapeutics Newsroom

Flagship Pioneering Announces Two New Agreements With Ampersand Biomedicines and Montai Therapeutics Under Its Strategic Partnership With Pfizer

PR Newswire19:30

Foghorn Therapeutics (FHTX) Collaborates With Eli Lilly and Surpasses Q3 Expectations

TipRanksNov 13 18:47

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswireNov 12 20:54

Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results.

BenzingaNov 6 04:51

H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20

Futu NewsNov 5 19:36 · Ratings

TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating

Futu NewsNov 5 08:33 · Ratings

TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)

TipRanksNov 5 08:16 · Ratings

Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates

Zacks Nov 5 05:45

Express News | Foghorn Therapeutics Inc.: Cash, Cash Equivalents, and Marketable Securities of $267.4 Mln as of September 30, 2024, Provides Cash Runway Into 2027

BreakingsNov 5 05:31

Foghorn Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 5 05:22 · Announcements

Press Release: Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update

Dow JonesNov 5 05:05

Express News | Foghorn Therapeutics Q3 Collaboration Revenue USD 7.808 Million

BreakingsNov 5 05:05

Express News | Foghorn Therapeutics Q3 Net Income USD -19.122 Million

BreakingsNov 5 05:05

Express News | Foghorn Therapeutics Q3 EPS USD -0.31

BreakingsNov 5 05:05

Express News | Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

BreakingsOct 23 20:00

Press Release: Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence

Dow JonesOct 23 20:00

More Unpleasant Surprises Could Be In Store For Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares After Tumbling 28%

Simply Wall StOct 22 18:43

Foghorn Therapeutics Unveils Clinical Pipeline Progress

TipRanksOct 10 19:47

Express News | Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral Smarca2 Selective Inhibitor Fhd-909 in a Phase 1 Trial for Smarca4 Mutated Solid Tumors

BreakingsOct 10 19:00

Foghorn Therapeutics Announces First Patient Dosed With First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors

Yahoo FinanceOct 10 19:00